Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21863674 | 0.76 | KDM4E (0.33) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL31449486 | 0.74 | NPC1 (0.38) | KDM4EMGLLALDH1A1NPC1RAB9A | |
| SCHEMBL29935760 | 0.72 | PDE4A (0.41) | ALDH1A1NPC1RAB9A | |
| SCHEMBL31449128 | 0.71 | KDM4E (0.50) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL21849018 | 0.71 | KDM4E (0.44) | KDM4EMGLLALDH1A1 | |
| SCHEMBL31449610 | 0.71 | ENPP3 (0.47) | KDM4EMGLLALDH1A1NPC1RAB9A | |
| SCHEMBL21848974 | 0.70 | KDM4E (0.39) | KDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL23531019 | 0.69 | ALDH1A1 (0.56) | KDM4EALDH1A1NPC1RAB9A | |
| Potassium Ion SCHEMBL21816151 | 0.69 | MGLL (0.38) | KDM4EMGLLALDH1A1RAB9A | |
| SCHEMBL21816080 | 0.66 | KMT2A (0.60) | KDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2800/4885MGLL 1/4885ALDH1A1 344/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885MGLL 1/4885ALDH1A1 312/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885MGLL 1/4885ALDH1A1 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.